NovoCure Limited (NVCR)

Market Cap	1.28B
Revenue (ttm)	630.16M
Net Income (ttm)	-170.95M
Shares Out	111.80M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,317,632
Open	11.62
Previous Close	11.76
Day's Range	11.30 - 11.94
52-Week Range	10.91 - 34.13
Beta	0.61
Analysts	Buy
Price Target	28.79 (+151.88%)
Earnings Date	Jul 24, 2025

About CALT

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,488
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.

Financial numbers in EUR

Analyst Summary

According to 7 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $28.79, which is an increase of 151.88% from the latest price.

Price Target

$28.79

(151.88% upside)

Analyst Consensus: Buy